Amgen shares are down due to a negative read-across from Novartis's failed pelacarsen trial, raising concerns about Amgen's similar drug, olpasiran. This sentiment is compounded by a BMO Capital downgrade, indicating a shift in analyst confidence and potentially impacting investor perception of Amgen's near-term growth prospects.
The headline presents a significant corporate catalyst for Amgen, driven by a negative read-across from a competitor's failed drug trial. The 'sympathy' selling indicates investor concern that Amgen's similar drug, olpasiran, might face similar challenges, impacting its future revenue potential. The BMO Capital downgrade further solidifies this negative sentiment, suggesting a loss of analyst confidence. This situation creates downside risk for Amgen and potentially other companies developing similar therapies, leading to increased volatility and a cautious trading environment within the pharmaceutical sector, particularly for those with drugs in late-stage trials for similar indications.